7Wittig JC, Bickels J, Priebat D, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician, 2002, 65 : 1123-1132.
8Bacci G, Ferrari S, Lari S, et al. Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br, 2002, 84: 88-92.
9Meyers PA, Gorlick R, Heller G, et al. Intensification of Preoperative Chemotherapy for Osteogenic Sarcoma: Results of the Memorial Sloan-Kettering (T12) Protocol. J Clin Oncol, 1998, 16 :2452-2458.
10Kushner BH, Meyem PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol, 2001, 19: 870-880.
4Du CW, Li D, Lin Y, et al. Differentiation of human nasopharyngeal carcinoma xenografts and repression of telomerase activity induced by arsenic trioxide. National Medical Journal of India,2004,17:67-70.
5Jemal A,Siegel R,Ward E,et al. Cancer statistics,2009. CA Cancer J Clin, 2009,59 : 225 -249.
6Han B, Zhou G, Zhang Q, et al. Effect to farsenic trioxide ( ATO ) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2. The oncol,2004,4:335-342.
7Brueckl WM, Schoeberl A, Wirtz RM, et al. Increased vascular-endo- thdial growth factor(VEGF) tumor expression and response to epider- mal growth factor receptor(EGF-R) inhibitor erlotinib in non-small cell lung cancer(NSCLC). J Thorac Oncol,2008,3:314-316.
8Stroescu C, Dragnea A, Ivanov B, et al. Expression of p53, B cl-2, VEGF, K i67 and PCNA and prognostic significance in hepatocellular carcinoma. J Gastrointestin Liver Dis ,2008,17:411-417.
9Ioachim E. Expression patterns of cyclins D1 ,E and cyclin dependent kinase inhibitors p21 w afl/cipl, p27kipl in colorectal careinoma: cor- relation with other cell cycle regutators(pRb,p.53 and Ki-67 and PC- NA) and clinicopathological features. Int J Clin Pract, 2008,62: 1736-1743.
